Disparities in Access to Care for Ph+ ALL patients
The panel discusses disparities in the quality of care received by Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.
Source: ajmc.com
Oph All News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Oph All. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Oph All Today - Breaking & Trending Today
Optimizing Real-World Ponatinib Use in Ph+ ALL: Treatment Considerations
Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS.
Source: onclive.com
Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights
Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.
Source: onclive.com
Advancing the Treatment Landscape in Philadelphia-Positive ALL
Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.
Source: onclive.com
First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL
Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
Source: onclive.com